title: Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study.
authors.affiliation: Meyer Children's Hospital, Rambam Medical Center, Haifa, Israel.
authors.forename: Riva
authors.initials: R
authors.lastname: Brik
authors.forename: Yonatan
authors.initials: Y
authors.lastname: Butbul-Aviel
authors.forename: Sari
authors.initials: S
authors.lastname: Lubin
authors.forename: Eliad
authors.initials: E
authors.lastname: Ben Dayan
authors.forename: Tamar
authors.initials: T
authors.lastname: Rachmilewitz-Minei
authors.forename: Lillian
authors.initials: L
authors.lastname: Tseng
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Hashkes
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000378:metabolism; D002648:Child; D003078:Colchicine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D010505:Familial Mediterranean Fever / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D053583:Interleukin-1beta / Q000276:immunology*; D008297:Male; D017063:Outcome Assessment, Health Care; D010865:Pilot Projects; D013997:Time Factors; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053583:Interleukin-1beta; C541220:canakinumab; D002097:C-Reactive Protein; D003078:Colchicine